<DOC>
	<DOCNO>NCT00002222</DOCNO>
	<brief_summary>The purpose study see valganciclovir safe treatment CMV retinitis patient treat condition past . This study also examine effectiveness valganciclovir prevent recurrence CMV retinitis .</brief_summary>
	<brief_title>A Study Valganciclovir Treatment Cytomegalovirus ( CMV ) Retinitis Patients With AIDS</brief_title>
	<detailed_description>Patients receive valganciclovir twice day 21 day induction therapy daily maintenance therapy . Patients encourage remain study least 3 month remain common study closure .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed caution : Acyclovir . Famciclovir . Valaciclovir . Imipenemcilastatin . Myelosuppressive agent . Patients must : HIV infection CMV retinitis . Minimum 4 week prior treatment ganciclovir , foscarnet , cidofovir . Intraocular implant either eye , long CMV retinitis active one eye , upon approval Roche . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active extraocular CMV disease . Severe uncontrolled diarrhea evidence malabsorption . Concurrent Medication : Excluded : Foscarnet . Cidofovir . CMV hyperimmune globulin . Probenecid . Patients follow prior condition exclude : Ocular medium opacity ( corneal , aqueous , lens , vitreous ) prevent ophthalmologic retinal assessment . Simultaneous participation another study ( unless approve Roche ) . Required : A minimum 4 week treatment ganciclovir , foscarnet , cidofovir . Approval require prior use investigational antiCMV agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>Cytomegalovirus Retinitis</keyword>
	<keyword>Prodrugs</keyword>
</DOC>